Skip to main content

Cormorant Asset Management — Portfolio, Page 8

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

205
Companies
$18.6B
Total invested
$120.0M
Avg. check
21
Industries
Biotechnology 17Health Care 17Medical 9Pharmaceutical 9Life Science 7Therapeutics 7+15 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 169192 of 205
Synnovation Therapeutics
December 2023

Synnovation Therapeutics is a precision oncology company that develops therapeutics that aims to help people with cancer.

Biotechnology · Wilmington$102.0M Series A
Verve Therapeutics
November 2023

Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.

Biotechnology · Boston$143.8M Post Ipo Equity
Harpoon Therapeutics
October 2023

Harpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.

Biotechnology · South San Francisco$100.0M Post Ipo Equity
Nexo Therapeutics
July 2023

Nexo Therapeutics offers treatments for some of cancer's most intractable targets.

Biotechnology · Littleton$60.0M Series A
Myra Vision
June 2023

Myra Vision develops a treatment that allows maximum IOP reduction for patients with moderate to severe glaucoma.

Health Care · Campbell$25.0M Series B
Elevation Oncology
June 2023

Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.

Biopharma · New York$50.0M Post Ipo Equity
connectRN
May 2023

ConnectRN is a tech-enabled network built to improve clinicians' lives through access to community, opportunity, and support.

Health Care · Waltham$750K Convertible Note
Icosavax
May 2023

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.

Biotechnology · Seattle$67.8M Post Ipo Equity
Ventus Therapeutics
April 2023

Ventus Therapeutics develops small molecule drugs that target autoimmune diseases, inflammatory diseases, and cancer.

Biotechnology · Waltham$150K Grant
Pliant Therapeutics
January 2023

Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

Biotechnology · South San Francisco$287.5M Post Ipo Equity
BlissBio
January 2023

Bliss Bio is a biopharmaceutical company focused on development of tumor targeting and immunotherapy drugs.

Biopharma · Hangzhou$14.8M Series B
Tricida
October 2022

Tricida operates in the healthcare industry focusing on pharmaceutical business.

Health Care · Menlo Park$125.0M Post Ipo Debt
Kezar Life Sciences
October 2022

Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders

Health Care · South San Francisco$12.2M Post Ipo Equity
RayzeBio
September 2022

RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.

Biotechnology · San Diego$160.0M Series D
Axonics Modulation Technologies
August 2022

Axonics Modulation Technologies is a pre-revenue company developing novel implantable neuromodulation.

Health Diagnostics · Irvine$111.7M Post Ipo Equity
MOMA Therapeutics
May 2022

MOMA Therapeutics operates as a biotechnology company.

Biotechnology · Cambridge$150.0M Series B
Arkuda Therapeutics
February 2022

Arkuda Therapeutics is a pharmaceutical company.

Biotechnology · Cambridge$64.0M Series B
Twist Bioscience
February 2022

Twist Bioscience is a biotechnology company that offers synthetic DNA solutions, gene synthesis, and variant libraries.

B2B · San Francisco$250.0M Post Ipo Equity
908 Devices
November 2021

908devices manufactures battery-operated, hand-held chemical detection tools used in mass spectrometry.

Battery · Boston$101.0M Post Ipo Equity
Stablix
June 2021

Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS).

Biotechnology · New York$63.0M Series A
NiKang Therapeutics
May 2021

NiKang Therapeutics is a biotech company focused on discovering and developing small molecule oncology medicines.

Biotechnology · Wilmington$200.0M Series C
Elpiscience Biopharmaceuticals
May 2021

Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies

Biopharma · Shanghai$105.0M Series C
Renovia
April 2021

Renovia was a developer of prescription digital therapeutics for pelvic floor disorders. Renovia ceased operations in late 2022.

Health Care · Boston$17.0M Series C
Graphite Bio
March 2021

Graphite Bio is a next-generation gene editing company that is driven to apply our breakthrough technology.

Biotechnology · South San Francisco$150.7M Series B

Where Cormorant Asset Management invests

Biotechnology17
Health Care17
Medical9
Pharmaceutical9
Life Science7
Therapeutics7

About Cormorant Asset Management's portfolio

How many companies has Cormorant Asset Management invested in?

Cormorant Asset Management has invested in 205 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Cormorant Asset Management invest in?

Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Life Science. The firm invests across 21 different industry categories.

What is Cormorant Asset Management's largest investment?

Among tracked funding rounds, Pliant Therapeutics received $287.5M in a Post Ipo Equity round. Cormorant Asset Management's total known invested capital is $18.6B.

What is the average investment size for Cormorant Asset Management?

Cormorant Asset Management's average investment size is $120.0M across its portfolio of 205 companies.

What are Cormorant Asset Management's most recent investments?

Recent Cormorant Asset Management portfolio additions include Synnovation Therapeutics, Verve Therapeutics, Harpoon Therapeutics, Nexo Therapeutics, Myra Vision. These companies were founded in 2020 or later.

Reach the founders behind these 205 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →